People living with HIV have a higher risk of developing shingles because HIV can weaken the immune system. Shingles causes a painful rash when the virus responsible for chickenpox becomes active again. Early medical care is important because antiviral medicines can help control the infection and reduce complications. Treatment decisions depend on the extent of the rash, immune health, and whether other organs are affected.
How are shingles and HIV connected?
Shingles, also called herpes zoster, develops when the varicella-zoster virus (VZV), which causes chickenpox, becomes active again after remaining inactive in the body. Anyone who has had chickenpox or acquired the virus can develop shingles, but the risk is higher when the immune system cannot control the virus as effectively.
HIV affects immune cells, including CD4 T cells, which help the body respond to infections. When HIV is untreated or has significantly reduced immune function, the risk of shingles and its complications increases. Effective antiretroviral therapy (ART) helps control HIV and supports immune recovery, although it does not eliminate the possibility of shingles.
According to the National Institutes of Health (NIH) HIV clinical guidelines, shingles occurs more frequently in people with HIV than in the general population, even in the era of effective HIV treatment. The risk is particularly relevant when immune function is impaired.
Does developing shingles mean that HIV is getting worse?
No. Shingles alone does not establish that HIV is progressing or that treatment has stopped working. It can occur in people whose HIV is well controlled, including those taking ART consistently. However, an episode may prompt a healthcare professional to review the person's HIV treatment, recent CD4 count, and viral load, particularly when shingles is widespread, recurrent, or unusually complicated.
For someone who has not previously been diagnosed with HIV, shingles is also not proof of HIV infection. It has several possible risk factors, including older age and other conditions or medicines that weaken the immune system. If testing is appropriate based on a person's circumstances, a healthcare professional can recommend the relevant tests rather than drawing conclusions from shingles alone.
What symptoms of shingles should people with HIV know about?
Shingles often begins with discomfort in a limited area of the skin before a rash appears. The symptoms may be more extensive or complicated in people with weakened immune systems, so new or unusual symptoms deserve prompt medical attention.
- Pain, burning, itching, or tingling: These sensations may occur in the area where the rash later develops.
- A blistering rash: Clusters of fluid-filled blisters commonly appear on one side of the body or face, often in a band-like pattern.
- Skin sensitivity: Clothing or light touch may cause discomfort in the affected area.
- Other symptoms: Fever, headache, tiredness, or general discomfort may accompany the rash.
- More widespread skin changes: In some people with substantial immune suppression, lesions may extend beyond the usual localized area.
The Centers for Disease Control and Prevention (CDC) notes that shingles can cause complications such as persistent nerve pain, eye problems, and neurological illness. A rash affecting the forehead, nose, or area around an eye is particularly concerning because the infection may threaten vision.
When should someone with HIV seek medical care?
Anyone living with HIV who develops a new blistering rash or unexplained burning skin pain should contact a healthcare professional promptly. Early assessment helps determine whether the symptoms are caused by shingles and whether antiviral treatment is needed. Treatment generally works best when started early, so it is better not to wait for the rash to spread or the blisters to crust over.
Seek urgent medical assessment if the rash affects the eye or nose, vision changes occur, the rash spreads widely, or symptoms are accompanied by severe headache, confusion, weakness, or other neurological changes. Severe illness, breathing difficulties, or rapidly worsening symptoms may require emergency care.
A clinician may be able to identify shingles from its appearance and pattern. If the presentation is unusual, a sample from a skin lesion may be tested for VZV. In people with HIV, the evaluation may also include a review of immune status and current medicines to help guide treatment.
How is shingles treated in people living with HIV?
Antiviral medicines are the main treatment for shingles. They act against the virus, help limit new lesion formation, and can support healing. The choice of medicine, route of administration, and treatment duration depend on the infection's extent, the person's clinical condition, kidney function, and other relevant factors.
Antiviral medicines
For localized shingles, clinicians commonly prescribe oral antiviral medicines such as acyclovir, valacyclovir, or famciclovir. The NIH recommends starting treatment as soon as possible, ideally within one week of rash onset or before all lesions have crusted. People with HIV may need a longer course or closer follow-up depending on how the infection responds.
When shingles is widespread, affects internal organs, or causes severe complications, hospital assessment and intravenous acyclovir may be necessary. Treatment may later change to an oral medicine when the person's condition improves and the healthcare team considers it appropriate. The NIH guidance on treatment of HIV-associated opportunistic infections provides recommendations for these different clinical situations.
Pain relief and skin care
Shingles can cause pain that continues even after the rash heals. A healthcare professional can recommend suitable pain relief based on the person's other medicines, kidney function, and medical history. Cool compresses, loose clothing, and gentle skin care may help reduce discomfort. Keep affected areas clean, avoid scratching the blisters, and follow clinical instructions for wound care.
Persistent or worsening pain should be discussed with a clinician. Some people develop postherpetic neuralgia, a complication in which nerve pain continues after the skin lesions have healed. Treatment may require medicines specifically used for nerve pain.
Should HIV treatment be changed during shingles?
People who take ART should generally continue it as prescribed unless their HIV clinician advises otherwise. Shingles does not automatically require a change in HIV medicines. The care team should review possible drug interactions before adding antiviral or pain-relief medicines, and assess whether HIV treatment is adequately controlling the virus.
When HIV is not yet treated or is not well controlled, the clinician can review the need to start or adjust ART. Decisions about timing should consider the person's overall condition, other infections, and potential medication interactions.
Can shingles cause serious complications in people with HIV?
Many episodes of shingles remain localized and heal with treatment. However, weakened immune function can increase the risk of complications, including more extensive skin disease and involvement of other organs. The risk depends on individual health factors and should not be judged by the appearance of the rash alone.
- Postherpetic neuralgia: Nerve pain that continues after the rash has healed.
- Eye complications: Involvement of the eye can cause inflammation and, in some cases, lasting vision damage.
- Disseminated shingles: The infection spreads beyond the usual localized area of skin.
- Neurological complications: In uncommon cases, VZV can affect the brain or other parts of the nervous system.
- Internal organ involvement: Severe infection can affect organs such as the lungs or liver, particularly in people with substantial immune suppression.
These complications are not inevitable. Prompt antiviral treatment, appropriate monitoring, and effective HIV care are important parts of reducing risk.
How can people with HIV reduce their risk of shingles?
Prevention combines HIV management with vaccination and practical measures to reduce the spread of VZV. Keeping scheduled HIV appointments, taking ART as prescribed, and monitoring CD4 counts and viral load help the healthcare team assess immune health and identify treatment needs.
Shingles vaccination
The recombinant zoster vaccine, known as Shingrix, helps prevent shingles and related complications. It is not a treatment for an active shingles episode. In the United States, the CDC recommends two doses for adults aged 19 years and older who are or will be immunodeficient or immunosuppressed because of a disease or treatment. This includes adults living with HIV.
The CDC's guidance for immunocompromised adults explains that the second dose is usually given two to six months after the first, although a shorter interval may be appropriate for some people. The NIH also recommends two doses for adults with HIV, regardless of CD4 count or previous shingles history. A clinician can help determine the best timing, especially after a recent diagnosis of HIV, during immune recovery, or following a shingles episode.
Shingrix is a non-live vaccine. It is different from the live varicella vaccine used to prevent chickenpox, which has separate considerations for people with HIV. Vaccine recommendations and availability can vary by country, so people outside the United States should check local guidance and discuss eligibility with their healthcare professional.
Reducing transmission during an active episode
Shingles itself is caused by reactivation of a virus already present in the body; it is not acquired from another person who has shingles. However, fluid from active shingles blisters can transmit VZV to someone who has no immunity to the virus, causing chickenpox rather than shingles.
Until the blisters have dried and crusted over, cover the rash when possible, wash hands regularly, and avoid direct contact between the lesions and people who may be particularly vulnerable, including pregnant people without immunity, newborns, and people with weakened immune systems. Follow any additional precautions advised by the treating healthcare team.
What should ongoing care look like after shingles?
Follow-up should confirm that the rash is healing, pain is improving, and no complications have developed. People with HIV may benefit from a review of their latest CD4 count, viral load, ART adherence, and vaccination status. If the rash persists, new lesions continue to appear, or symptoms return, the clinician may need to reassess the diagnosis and treatment plan.
After the episode resolves, eligible adults who have not received Shingrix should discuss vaccination with their healthcare professional. Vaccination can help protect against future episodes, although it cannot guarantee that shingles will never occur again.
Living with HIV does not mean that shingles or its complications are unavoidable. Timely medical care, appropriate antiviral treatment, continued HIV management, and recommended vaccination can help protect health and support recovery.